Get started
Author

María Otaño

Observed names: M Otano, M. Otano, M. Otaño, Maria Otaño, María Otano, Otaño, María
ORCID: 0000-0001-7053-1817
Observed ORCID: 0000-0001-7053-1817
OpenAlex ID: A5021823476
Cortico-juxtacortical involvement increases risk of epileptic seizures in multiple sclerosis
2013 · E. H. Martínez-Lapiscina, T. Ayuso, et al. · Acta Neurologica Scandinavica · 37
PDF
Vitamin D receptor gene is epigenetically altered and transcriptionally up-regulated in multiple sclerosis
2017 · Teresa Ayuso, Patricia Aznar, et al. · PLoS ONE · 32
PDF
New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab
2020 · Inmaculada Toboso, Amalia Tejeda-Velarde, et al. · Frontiers in Neurology · 17
PDF
A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer
2024 · Joanna I. López-Velazco, Sara Manzano, et al. · Breast Cancer Research · 13
PDF
Cognitive deterioration in multiple sclerosis
2009 · P de Castro, A Aranguren, et al. · Anales del Sistema Sanitario de Navarra · 6
PDF
Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response
2025 · Joanna I. López-Velazco, Sara Manzano, et al. · Translational Oncology · 4
Cbio-06. Potential Role of Rnu6 Isolated From Circulating Exosomes as a Diagnostic Biomarker for Glioblastoma
2017 · Montserrat Puigdelloses, Marisol González-Huarriz, et al. · Neuro-Oncology · 1
PDF
Abstract PS4-03-16: Characterization of the cytokine profile of metastatic Breast Cancer, from mediators of chronic inflammation to potential biomarkers
2026 · M. M. Caffarel, U. Alvarez, et al. · Clinical Cancer Research
Abstract PS1-11-01: Impact of prior CDK 4/6 inhibitor treatment on the efficacy of everolimus and exemestane or fulvestrant in hormone receptor positive HER 2 negative (HR+/HER2-) metastatic breast cancer (MBC): a restrospective analysis of 144 patients
2026 · M. Otaño, A. Paisan, et al. · Clinical Cancer Research
27P Dissecting the dynamics of the cytokine profile in breast cancer patients: From mediators of chronic inflammation to potential biomarkers
2025 · S. Manzano, U. Álvarez, et al. · Immuno-Oncology Technology
Molecular Characterisation of the Residual Disease after Neoadjuvant Endocrine Therapy in Er+/Her2- Breast Cancer Uncovers Biomarkers of Tumour Response
2025 · Joanna I. López-Velazco, Sara Manzano, et al. · SSRN Electronic Journal
Molecular characterization of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response
2024 · Joanna I. López-Velazco, Sara Manzano, et al. · Research Square
PDF
Molecular Characterisation of the Residual Disease after Neoadjuvant Endocrine Therapy in Er+/Her2- Breast Cancer Uncovers Biomarkers of Tumour Response
2024 · Joanna I. López-Velazco, Sara Manzano, et al. · SSRN Electronic Journal
Abstract P2-15-01: Conversion from luminal to normal intrinsic subtype by PAM50 after neoadjuvant endocrine therapy is associate with biomarkers of good prognosis in luminal breast cancer
2022 · Joanna Ines Lopez Velazco, María Otaño, et al. · Cancer Research
Abstract PS5-39: Tumour cellularity size as a biomarker to predict response after neoadjuvant endocrine therapy: Correlation analysis between Ki67 expression and PEPI score
2021 · Joanna Ines Lopez Velazco, María Otaño, et al. · Cancer Research
110P Primary endocrine therapy of breast cancer: Is there a good radiological technique to define pathological response?
2020 · J.I. Lopez Velazco, M. Otaño, et al. · Annals of Oncology
4-31-02 Gadolinium enhancement in patients with multiple sclerosis (MS)
1997 · P. de Castro, M. Otano, et al. · Journal of the Neurological Sciences
3-31-03 Lymphocyte subsets in multiple sclerosis (MS) patients
1997 · P. de Castro, M. Otano, et al. · Journal of the Neurological Sciences
Increase of CD4+CD29+ cells in patients with multiple sclerosis
1995 · M. Carreño, P. de Castro, et al. · Journal of Neuroimmunology
Works count: 21
Citation count: 110
H-index: 5
I10-index: 4
Year
Topic
Type